antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2020-65-1-2-61-67antibiotics-711Research ArticleОБЗОРЫREVIEWSВакцинация в ревматологии: новые данные (по материалам рекомендаций Европейской антиревматической лиги - EULAR)Vaccination in Rheumatology: New Data (Based on Recommendations of the European League Against Rheumatism)БеловБ. С.BelovB. S.

Москва

Moscow

belovbor@yandex.ruТарасоваГ. М.TarasovaG. M.

Москва

Moscow

МуравьеваН. В.MuravyovaN. V.

Москва

Moscow

ФГБНУ НИИ ревматологии им. В. А. НасоновойРоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202025052020651-26167Copyright © Белов Б.С., Тарасова Г.М., Муравьева Н.В., 20202020Белов Б.С., Тарасова Г.М., Муравьева Н.В.Belov B.S., Tarasova G.M., Muravyova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/711

В современной ревматологии коморбвдные инфекции оказывают значительное влияние на морбидность и летальность, особенно при иммуновоспалигельных ревматических заболеваниях (ИВРЗ). В связи с этим всё большее значение в профилактике инфекций при ИВРЗ приобретает вакцинация. В настоящей статье проанализирован обновлённый вариант рекомендаций по вакцинации взрослых больных с ИВРЗ, предложенный экспертами Европейской антиревматической лиги (EULAR) в конце 2019 г. Обсуждается безопасность и иммуногенность вакцинации, связанной с предупреждением различных инфекций у больных ИВРЗ. Обозначены основные направления будущих исследований по рассматриваемой проблеме.

Comorbid infections have a significant effect on morbidity and mortality in modern rheumatology, especially in immune-mediated inflammatory rheumatic diseases (IMIRD). In this regard, vaccination is becoming increasingly important in the prevention of infections in IMIRD. The article analyzes an updated version of the recommendations for vaccination of adult patients with IMIRD, proposed by experts of the European League Against Rheumatism at the end of 2019. The safety and immunogenicity of vaccination associated with the prevention of various infections in patients with IMIRD are discussed. The main directions of future research on this issue are outlined.

иммуновоспалительные ревматические заболеваниягрипппневмониявирус папилломы человекажёлтая лихорадкавакцинациярекомендацииimmune-mediated inflammatory rheumatic diseasesinfluenzapneumoniahuman papillomavirusyellow fevervaccinationrecommendationsReferencesБуханова Д.В., Белов Б.С., Тарасова Г.М. и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В. А. Насоновой). Медицинский совет. - 2019. - № 9. - С. 86-91.Buhanova D.V., Belov B.S., Tarasova G.M. et al. Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova). Meditsinsky sovet 2019; 9: 86–91 [In Russian].Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.Kiltz U., Celik A., Tsiami S. et al. Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (Suppl 10), abstr.264.Kiltz U., Celik A., Tsiami S. et al. Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (Suppl 10), abstr.264.Qendro T., de la Torre M.L., Panopalis P. et al. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. J Rheumatol 2019 Jul 15. Published online December 1, 2019. doi: 10.3899/jrheum.181376Qendro T., de la Torre M.L., Panopalis P. et al. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. J Rheumatol 2019 Jul 15. Published online December 1, 2019. doi: 10.3899/jrheum.181376Feldman C., Xu C., Costenbader K. Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences [abstract]. Arthritis Rheumatol. 2019; 71 (Suppl 10). abstr.951.Feldman C., Xu C., Costenbader K. Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences [abstract]. Arthritis Rheumatol. 2019; 71 (Suppl 10). abstr.951.Nguyen M., Lindegaard H., Hendricks O., Friis-Møller N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol 2017; 46 (6): 446–453.Nguyen M., Lindegaard H., Hendricks O., Friis-Møller N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol 2017; 46 (6): 446–453.Loubet P., Kernéis S., Groh M. et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 2015; 33 (31): 3703–3708.Loubet P., Kernéis S., Groh M. et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 2015; 33 (31): 3703–3708.Ribeiro A.C.M., Guedes L.K.N., Moraes J.C.B. et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011;70: 2144–2147.Ribeiro A.C.M., Guedes L.K.N., Moraes J.C.B. et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011;70: 2144–2147.Наумцева М.С., Белов Б.С., Александрова E.H. и др. Оценка иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных ревматическими заболеваниями. Научно-практическая ревматология. - 2015. - Т. 53. - № 6. - С. 586-590.Naumtseva M.S., Belov B.S., Aleksandrova E.N. et al. Assessment of the immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatic diseases. Nauchno-prakticheskaya revmatologiya=Rheumatology Science and Practice 2015; 53 (6): 586–590 [In Russian].Тарасова Г.М., Белов Б.С., Буханова Д.В. и др. Изучение иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных системной красной волчанкой. Научно-практическая ревматология. - 2018. - Т. 56. - № 4. - С. 433-438.Tarasova G.M., Belov B.S., Bukhanova D.V. et al. Investigation of immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice 2018; 56(4): 433–438. [In Russian.].Subesinghe S., Bechman K., Rutherford A.I. et al. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45 (6): 733–744.Subesinghe S., Bechman K., Rutherford A.I. et al. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45 (6): 733–744.Winthrop K.L., Silverfield J., Racewicz A. et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016; 75 (4): 687–695.Winthrop K.L., Silverfield J., Racewicz A. et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016; 75 (4): 687–695.Broyde A., Arad U., Madar-Balakirski N. et al. Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. J Rheumatol 2016; 43 (2): 267–272.Broyde A., Arad U., Madar-Balakirski N. et al. Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. J Rheumatol 2016; 43 (2): 267–272.Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3): 309–318.Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3): 309–318.Heijstek M.W., van Gageldonk P.G., Berbers G.A. et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis 2012; 71 (6): 948–954.Heijstek M.W., van Gageldonk P.G., Berbers G.A. et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis 2012; 71 (6): 948–954.Heijstek M.W., Kamphuis S., Armbrust W. et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309 (23): 2449–2456.Heijstek M.W., Kamphuis S., Armbrust W. et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309 (23): 2449–2456.Heijstek M.W., Kamphuis S., Armbrust W. et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309 (23): 2449–2456.Heijstek M.W., Kamphuis S., Armbrust W. et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309 (23): 2449–2456.Chang C.C., Chang Y.S., Chen W.S. et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep 2016; 6: 37817.Chang C.C., Chang Y.S., Chen W.S. et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep 2016; 6: 37817.Kobashigawa T., Nakajima A., Taniguchi A. et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 2013; 42 (6): 445–450.Kobashigawa T., Nakajima A., Taniguchi A. et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 2013; 42 (6): 445–450.van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62 (1): 75–81.van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62 (1): 75–81.Arad U., Tzadok S., Amir S. et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29 (8): 1643–1648.Arad U., Tzadok S., Amir S. et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29 (8): 1643–1648.Richi P., Martín M.D., Navío M.T. et al. Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study. Med Clin (Barc) 2019 Nov 29; 153 (10): 380–386.Richi P., Martín M.D., Navío M.T. et al. Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study. Med Clin (Barc) 2019 Nov 29; 153 (10): 380–386.Lakota K., Perdan-Pirkmajer K., Sodin-Semrl S. et al. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective study. Clin Rheumatol 2019 May; 38 (5): 1277–1292.Lakota K., Perdan-Pirkmajer K., Sodin-Semrl S. et al. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective study. Clin Rheumatol 2019 May; 38 (5): 1277–1292.Nakafero G., Grainge M.J., Myles P.R. et al. Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink. Ann Rheum Dis 2019; 78 (8): 1122–1126.Nakafero G., Grainge M.J., Myles P.R. et al. Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink. Ann Rheum Dis 2019; 78 (8): 1122–1126.Park J.K., Lee Y.J., Shin K. et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 77 (6): 898–904.Park J.K., Lee Y.J., Shin K. et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 77 (6): 898–904.Gabay C., Bel M., Combescure C. et al. Impact of synthetic and biologic disease modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63: 1486–1496.Gabay C., Bel M., Combescure C. et al. Impact of synthetic and biologic disease modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63: 1486–1496.Milanetti F., Germano V., Nisini R. et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol 2014; 177 (1): 287–294.Milanetti F., Germano V., Nisini R. et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol 2014; 177 (1): 287–294.Adler S., Krivine A., Weix J. et al. Protective effect of A/H1N1 vaccination in immunemediated disease a prospectively controlled vaccination study. Rheumatology 2012; 51: 695–700.Adler S., Krivine A., Weix J. et al. Protective effect of A/H1N1 vaccination in immunemediated disease a prospectively controlled vaccination study. Rheumatology 2012; 51: 695–700.Kapetanovic M.C., Kristensen L.E., Saxne T. et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014; 16 (1): R2.Kapetanovic M.C., Kristensen L.E., Saxne T. et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014; 16 (1): R2.Elkayam O., Amir S., Mendelson E. et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63 (7): 1062–1067.Elkayam O., Amir S., Mendelson E. et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63 (7): 1062–1067.Miossi R., Fuller R., Moraes J.C. et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics (Sao Paulo) 2013; 68 (2): 129–134.Miossi R., Fuller R., Moraes J.C. et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics (Sao Paulo) 2013; 68 (2): 129–134.Borte S., Liebert U.G., Borte M., Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009; 48 (2): 144–148.Borte S., Liebert U.G., Borte M., Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009; 48 (2): 144–148.Curtis J.R., Yang S., Patkar N.M. et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66 (7): 990–997.Curtis J.R., Yang S., Patkar N.M. et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66 (7): 990–997.Shea K.M., Edelsberg J., Weycker D. et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1 (1): ofu024.Shea K.M., Edelsberg J., Weycker D. et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1 (1): ofu024.Coulson E., Saravanan V., Hamilton J. et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011; 70 (7): 1289–1291.Coulson E., Saravanan V., Hamilton J. et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011; 70 (7): 1289–1291.Tsuru T., Terao K., Murakami M. et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 2014; 24: 511–516.Tsuru T., Terao K., Murakami M. et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 2014; 24: 511–516.Migita K., Akeda Y., Akazawa M. et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther 2015; 17: 149.Migita K., Akeda Y., Akazawa M. et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther 2015; 17: 149.Bingham C.O. 3rd, Rizzo W., Kivitz A. et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 2015; 74 (5): 818–822.Bingham C.O. 3rd, Rizzo W., Kivitz A. et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 2015; 74 (5): 818–822.Rezende R.P.V., Ribeiro F.M., Albuquerque E.M.N. et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus 2016; 25: 1254–1259.Rezende R.P.V., Ribeiro F.M., Albuquerque E.M.N. et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus 2016; 25: 1254–1259.Белов Б.С. Вакцинация при ревматических заболеваниях: союзник или противник? Научно-практическая ревматология. - 2018. - Т. 56. - № 4. - С. 401-404.Belov B.S. Vaccination in rheumatic diseases: an ally or an enemy? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018; 56 (4): 401–404 [In Russian].Tarasova G., Belov B., Bukhanova D. et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis 2019; 78 (Suppl 2): 785–786.Tarasova G., Belov B., Bukhanova D. et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis 2019; 78 (Suppl 2): 785–786.Bukhanova D., Belov B., Tarasova G. et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis 2019; 78 (Suppl 2): 336.Bukhanova D., Belov B., Tarasova G. et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis 2019; 78 (Suppl 2): 336.Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816–819.Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816–819.Чучалин А.Г., Брико Н.И., Авдеев С.Н. и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. - 2019. - Т. 29. - № 1. - С. 19-34.Chuchalin A.G., Briko N.I., Avdeev S.N. et al. Federal ñlinical guidelines on preventive vaccination against pneumococcal infections in adults. Russian Pulmonology 2019; 29 (1): 19–34 [in Russian].Белов Б.С., Буханова Д.В., Тарасова Г.М. Вакцинация в ревматологии: настоящее и будущее. Антибиотики и химиотер. - 2018. - Т. 63. - №1-2. - С. 56-64.Belov B.S., Bukhanova D.V., Tarasova G.M. Vaccination in rheumatology: present and future. Antibiotiki i khimioter 2018; 63 (1–2): 56–64 [in Russian].Elkayam O., Ablin J., Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 2007 Apr; 6 (5): 312–314.Elkayam O., Ablin J., Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 2007 Apr; 6 (5): 312–314.Bukhanova D., Belov B., Tarasova G. et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis 2019; 78 (6): Suppl 2: A336.Bukhanova D., Belov B., Tarasova G. et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis 2019; 78 (6): Suppl 2: A336.Devey M. E., Bleasdale K., Isenberg D. A. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987; 68 (3): 562–569.Devey M. E., Bleasdale K., Isenberg D. A. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987; 68 (3): 562–569.Battafarano D.F., Battafarano N.J., Larsen L. et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998; 41 (10): 1828–1834.Battafarano D.F., Battafarano N.J., Larsen L. et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998; 41 (10): 1828–1834.Askling H.H., Rombo L., van Vollenhoven R. et al. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, openlabel,multi-centre study. Travel Med Infect Dis 2014; 12: 134–142.Askling H.H., Rombo L., van Vollenhoven R. et al. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, openlabel,multi-centre study. Travel Med Infect Dis 2014; 12: 134–142.van den Bijllaardt W., Siers H.M., Timmerman-Kok C. et al. Seroprotection after hepatitis A vaccination in patients with Drug-Induced immunosuppression. J Travel Med 2013; 20: 278–282.van den Bijllaardt W., Siers H.M., Timmerman-Kok C. et al. Seroprotection after hepatitis A vaccination in patients with Drug-Induced immunosuppression. J Travel Med 2013; 20: 278–282.Zhang J., Xie F., Delzell E. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43–49.Zhang J., Xie F., Delzell E. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43–49.Yun H., Xie F., Baddley J.W. et al. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol 2017; 44 (7): 1083–1087.Yun H., Xie F., Baddley J.W. et al. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol 2017; 44 (7): 1083–1087.Mok C.C., Ho L.Y., Fong L.S. et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72: 659–664.Mok C.C., Ho L.Y., Fong L.S. et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72: 659–664.Dhar J.P., Essenmacher L., Dhar R. et al. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine 2017; 35: 2642–2646.Dhar J.P., Essenmacher L., Dhar R. et al. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine 2017; 35: 2642–2646.Mok C.C., Ho L.Y., To C.H. Long-Term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine 2018; 36: 3301–3307.Mok C.C., Ho L.Y., To C.H. Long-Term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine 2018; 36: 3301–3307.Grönlund O., Herweijer E., Sundström K., Arnheim-Dahlström L. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med 2016; 280 (6): 618–626.Grönlund O., Herweijer E., Sundström K., Arnheim-Dahlström L. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med 2016; 280 (6): 618–626.Mahadevan U., Wolf D.C., Dubinsky M. et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-292.Mahadevan U., Wolf D.C., Dubinsky M. et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-292.Zelinkova Z., de Haar C., de Ridder L. et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053–1058.Zelinkova Z., de Haar C., de Ridder L. et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053–1058.Berthelsen B.G., Fjeldsoe-Nielsen H., Nielsen C.T. et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 2010; 49: 2225–2227.Berthelsen B.G., Fjeldsoe-Nielsen H., Nielsen C.T. et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 2010; 49: 2225–2227.Götestam Skorpen C., Hoeltzenbein M., Tincani A., et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75 (5): 795–810.Götestam Skorpen C., Hoeltzenbein M., Tincani A., et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75 (5): 795–810.

The authors declare that there are no conflicts of interest present.